FemHealth Focus
Sermonix and Regor Therapeutics Forge Strategic Alliance to Advance Targeted Therapies for Metastatic Breast Cancer
Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mB...
March 25, 2025 | News
Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer
Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...
March 24, 2025 | Report
TiumBio and Hansoh Pharma Gain Clinical Trial Approval in China for Merigolix in ART-Related Controlled Ovarian Stimulation
Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (con...
March 21, 2025 | News
Shanghai Henlius Secures FDA Orphan Drug Designation for HLX22 in Gastric Cancer
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for...
March 20, 2025 | News
Alphamab Oncology and CSPC’s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic...
March 19, 2025 | News
Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...
March 03, 2025 | News
Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...
February 28, 2025 | News
Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...
February 28, 2025 | News
Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...
February 24, 2025 | News
Akeso Doses First Patient in Phase III Trial of Ivonescimab for First-Line Treatment of Triple-Negative Breast Cancer
Akeso, Inc. announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of...
February 21, 2025 | News
Adalvo and Wyntra Launch First Women’s Health Treatment in the UK, Expanding Access for Endometriosis Care
Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, re...
February 20, 2025 | News
NERLYNX® Approved in Thailand for Early and Advanced HER2+ Breast Cancer Treatment
NERLYNX® (neratinib) has been approved as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitab...
February 18, 2025 | News
RemeGen Presents Promising Phase II Trial Results for Disitamab Vedotin and Toripalimab in Muscle-Invasive Bladder Cancer at ASCO GU 2025
RemeGen Co., Ltd. (RemeGen) has announced new efficacy and safety data from the Phase II clinical trial (NCT05297552, Study ID: RC48-C017) evaluating Disit...
February 17, 2025 | News
Alphamab Oncology Doses First Patient in Phase III Study of Anti-HER2 ADC JSKN003 for Platinum-Resistant Ovarian Cancer
Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...
February 14, 2025 | News
Most Read
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
